The primary purpose of the protocol is to evaluate the long-term safety of pregabalin in patients with partial seizures.

Inclusion Criteria:

• Patients must have met the inclusion criteria for Study 1008-157, have received double-blind study medication, and wish to receive open-label pregabalin
• Have the diagnosis of epilepsy with partial seizures and have a minimum of 4 partial seizures during the 6 weeks prior to screening
• Be currently taking 1 to 3 AEDs.

Exclusion Criteria:

• Have a treatable cause of seizures
• Experienced a serious adverse event during Study 1008-157 which was determined to be possibly related to study medication